Found: 17
Select item for more details and to access through your institution.
Effectiveness and safety of hFVIII/VWF concentrate (Voncento®) in patients with inherited von Willebrand disease requiring surgical procedures: the OPALE multicentre observational study.
- Published in:
- Blood Transfusion (17232007), 2021, v. 19, n. 2, p. 152, doi. 10.2450/2020.0246-20
- By:
- Publication type:
- Article
Bleeding risk for patients with haemophilia under antithrombotic therapy. Results of the French multicentric study ERHEA.
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 4, p. 764, doi. 10.1111/bjh.15606
- By:
- Publication type:
- Article
A Missense Mutation in the Alpha-Actinin 1 Gene (<i>ACTN1</i>) Is the Cause of Autosomal Dominant Macrothrombocytopenia in a Large French Family.
- Published in:
- PLoS ONE, 2013, v. 8, n. 9, p. 1, doi. 10.1371/journal.pone.0074728
- By:
- Publication type:
- Article
Predelivery Haemostatic Biomarkers in Women with Non-Severe Postpartum Haemorrhage.
- Published in:
- Journal of Clinical Medicine, 2024, v. 13, n. 14, p. 4231, doi. 10.3390/jcm13144231
- By:
- Publication type:
- Article
Effectiveness of long‐term prophylaxis using pdFVIII/VWF concentrate in patients with inherited von Willebrand disease.
- Published in:
- European Journal of Haematology, 2022, v. 109, n. 1, p. 109, doi. 10.1111/ejh.13778
- By:
- Publication type:
- Article
rFVIII‐Fc in severe haemophilia A: The incentive switch in case of high risk of joint bleedings.
- Published in:
- European Journal of Clinical Investigation, 2022, v. 52, n. 10, p. 1, doi. 10.1111/eci.13824
- By:
- Publication type:
- Article
A very potent factor V inhibitor interferes with the levels of all coagulation factors and causes a fatal hemorrhagic syndrome.
- Published in:
- European Journal of Haematology, 2019, v. 103, n. 2, p. 137, doi. 10.1111/ejh.13249
- By:
- Publication type:
- Article
Acquired von Willebrand syndrome and lymphoproliferative disorders: A case report.
- Published in:
- Clinical Case Reports, 2020, v. 8, n. 5, p. 900, doi. 10.1002/ccr3.2770
- By:
- Publication type:
- Article
Development and Validation of a Predictive Tool for Postpartum Hemorrhage after Vaginal Delivery: A Prospective Cohort Study.
- Published in:
- Biology (2079-7737), 2023, v. 12, n. 1, p. 54, doi. 10.3390/biology12010054
- By:
- Publication type:
- Article
Key Drivers of Coagulation Factor Use in Von Willebrand Disease During Hospitalization: An Overview of the French BERHLINGO Cohort.
- Published in:
- Clinical Drug Investigation, 2024, v. 44, n. 1, p. 35, doi. 10.1007/s40261-023-01323-1
- By:
- Publication type:
- Article
Differences between aquagenic and non‐aquagenic pruritus in myeloproliferative neoplasms: An observational study of 500 patients.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 6, p. 1175, doi. 10.1111/jdv.18990
- By:
- Publication type:
- Article
Modèle hub & spoke en France : organisation des soins et parcours des patients pour la thérapie génique de l'hémophilie.
- Published in:
- Hematologie, 2023, v. 29, n. 2, p. 88, doi. 10.1684/hma.2023.1779
- By:
- Publication type:
- Article
Biological determinants of bleeding in patients with heterozygous factor XI deficiency.
- Published in:
- British Journal of Haematology, 2012, v. 156, n. 2, p. 245, doi. 10.1111/j.1365-2141.2011.08945.x
- By:
- Publication type:
- Article
Acquired von Willebrand syndrome and lymphoid neoplasms: A review of malignancy management, and propositions of practical recommendations.
- Published in:
- Haemophilia, 2022, v. 28, n. 6, p. 938, doi. 10.1111/hae.14648
- By:
- Publication type:
- Article
Efficacy and safety of a recombinant Von Willebrand Factor treatment in patients with inherited Von Willebrand Disease requiring surgical procedures.
- Published in:
- Haemophilia, 2021, v. 27, n. 2, p. 270, doi. 10.1111/hae.14242
- By:
- Publication type:
- Article
Bleeding complications during pregnancy and delivery in haemophilia carriers and their neonates in Western France: An observational study.
- Published in:
- Haemophilia, 2020, v. 26, n. 6, p. 1046, doi. 10.1111/hae.14117
- By:
- Publication type:
- Article
Pegylated interferon 2a and ruxolitinib induce a high rate of oral complications among patients with myeloproliferative neoplasms.
- Published in:
- EJHaem, 2020, v. 1, n. 1, p. 1, doi. 10.1002/jha2.15
- By:
- Publication type:
- Article